AstraZeneca nearly halved the supply of Covid-19 shots to EU countries this week, prompting the agency to claim that the agency would be temporary and that this was due to delayed testing of a batch of vaccines.
According to documents seen in the Financial Times, the company in mid-March this week 2. The EU expects Iceland and Norway to supply 1.3 million doses to the EU’s two member states, more than the fore million forecast.
According to the document this cut is equal to 49 percent reduction and evenly distributed across the country.
AstraZeneca said it had informed the European Commission and member states last week that batch tests were needed and would be provided soon. It said it would meet its target of delivering m0 million doses in the second quarter.
“Weekly deliveries typically show small fluctuations depending on a variety of operational factors such as the delivery or completion of quality and safety tests,” the agency said.
The latest delays have been frustrating since the agency dramatically revised its forecast for EU supplies in recent months, with nearly a quarter of maximum target deliveries in the first quarter and more than half the evidence for the second.
Any shortage of the Oxford / AstraZeneca vaccine would be a fresh blow to the EU’s vaccination campaign – which lags behind the people of the United Kingdom, the United States and Israel – although the company’s job is less important in the blockchain program in the second quarter. This is more than the first.
Changes in supplies have hampered the European Union’s rollout, which has also slowed by changing the direction of who should be vaccinated after concerns were raised about the side effects of rare blood clots. They have caused tensions between the EU and the UK over possible export sanctions.
“There will be virtually no supplies this week,” said one person familiar with the conversation between drug manufacturers and member countries.
“And it will happen next week,” the person added. “It’s always happening.”
European leaders are no longer hiding their dissatisfaction with the organization. Italian Prime Minister Mario Draghi told reporters on Thursday that the failure to deliver the vaccine was caused by “certain organizations, especially AstraZeneca.”
“The feeling is one’s feeling – and perhaps, out of pity, it’s wrong – it’s because this dose has been sold two or three times,” Draghi added, adding that supply contracts were not honored. He described the “failures” as “unexpected, unexpected, unexplained”.
“We are developing, producing and supplying this vaccine without any profit, and we strongly reject any suggestion that we will sell the same dose more than once,” AstraZeneca responded to Draghi’s comments.
The man said the delivery cut came in a very brief notification this week, and AstraZeneca told member states that supply problems stemmed from problems with its plant production, with products not producing enough to keep the drug in vials.
AstraZeneca has previously identified the problem as one of the reasons behind its deficit. In this example, however, the company stated that it was wrong to cite problems with the production of drugs, which occurred much earlier in the case of manufacturing.
The delay in Europe came as the US announced that Johnson and Johnson’s dose would be reduced next week. The Centers for Disease Control and Prevention says production problems at a Baltimore production center, where 15 million doses were lost, will be reduced by 86 percent in the states.
A total of 4,94747,500 JZ doses were allocated at the beginning of April 5, with only 700,000,000 to be given from April to April.
The European Commission did not immediately respond to a request for comment.
Additional report by Niku Asgari in London